Long‐term results of the treatment of patients with mantle cell lymphoma with cladribine (2‐CDA) alone (95‐80‐53) or 2‐CDA and rituximab (N0189) in the North Central Cancer Treatment Group-Reference-Cited by-同舟云学术

Long‐term results of the treatment of patients with mantle cell lymphoma with cladribine (2‐CDA) alone (95‐80‐53) or 2‐CDA and rituximab (N0189) in the North Central Cancer Treatment Group

Published:2008-07-01 Issue:1 Volume:113 Page:108-116
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Inwards David J.,Fishkin Paul A. S.,Hillman David W.,Brown David W.,Ansell Stephen M.,Kurtin Paul J.,Fonseca Rafael,Morton Roscoe F.,Veeder Michael H.,Witzig Thomas E.

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference43 articles.

1. Mantle cell lymphoma: an update on management;Zelenetz;Ann Oncol.,2006

2. Current treatment approaches for mantle‐cell lymphoma;Witzig;J Clin Oncol.,2005

3. Molecular basis of mantle cell lymphoma;Bertoni;Br J Haematol.,2004

4. Mantle cell lymphoma;Kurtin;Adv Anat Pathol.,1998

5. Demonstration of distinct antigenic profiles of small B‐cell lymphomas by paraffin section immunohistochemistry;Kurtin;Am J Clin Pathol.,1999

Cited by 63 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Phase I Study using Bortezomib (Velcade), Cladribine, and Rituximab (VCR) in Treating Elderly Patients with Mantle Cell Lymphoma;2024-03-27

2. Epigenetic targets in B- and T-cell lymphomas: latest developments;Therapeutic Advances in Hematology;2023-01

3. Combined epigenetic and immunotherapy for blastic and classical mantle cell lymphoma;Oncotarget;2022-08-16

4. Mantle cell lymphoma management trends and novel agents: where are we going?;Therapeutic Advances in Hematology;2022-01

5. SAMHD1 Mutations and Expression in Mantle Cell Lymphoma Patients;Frontiers in Oncology;2021-12-17